{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:10:47Z","timestamp":1786975847053,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd009868.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T00:00:00Z","timestamp":1488758400000}}],"reference-count":217,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009868.pub3","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T11:31:16Z","timestamp":1488799876000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases"],"prefix":"10.1002","volume":"2017","author":[{"given":"Ehete","family":"Bahiru","sequence":"first","affiliation":[{"name":"Northwestern University; Internal Medicine; Division of Cardiology; 201 E. Huron St. Galter 19-100 Chicago Illinois USA 60611"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angharad N","family":"de Cates","sequence":"additional","affiliation":[{"name":"Warwick Medical School, University of Warwick; Division of Health Sciences; Coventry UK CV4 7AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew RB","family":"Farr","sequence":"additional","affiliation":[{"name":"Warwick Medical School, University of Warwick; Division of Health Sciences; Coventry UK CV4 7AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morag C","family":"Jarvis","sequence":"additional","affiliation":[{"name":"Warwick Medical School, University of Warwick; Division of Health Sciences; Coventry UK CV4 7AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Palla","sequence":"additional","affiliation":[{"name":"Wayne State University; Department of Medicine; 540 E Canfield St Detroit Michigan USA 48201"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Rees","sequence":"additional","affiliation":[{"name":"Warwick Medical School, University of Warwick; Division of Health Sciences; Coventry UK CV4 7AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shah","family":"Ebrahim","sequence":"additional","affiliation":[{"name":"London School of Hygiene & Tropical Medicine; Department of Non-communicable Disease Epidemiology; Keppel Street London UK WC1E 7HT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D","family":"Huffman","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine; Departments of Preventive Medicine and Medicine (Cardiology); 680 N. Lake Shore Drive, Suite 1400 Chicago IL USA 60611"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,6]]},"reference":[{"key":"10.1002\/14651858.CD009868.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.3346\/jkms.2013.28.12.1741","article-title":"Proactive multifactorial intervention strategy reduces the risk of cardiovascular disease estimated with region-specific risk assessment models in Pacific Asian patients participating in the CRUCIAL trial","volume":"28","author":"Cho","year":"2013","journal-title":"Journal of Korean Medical Science"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2147\/VHRM.S54586","article-title":"Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: a CRUCIAL trial subanalysis","volume":"10","author":"Cho","year":"2014","journal-title":"Vascular Health and Risk Management"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1185\/03007995.2013.783795","article-title":"Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial","volume":"29","author":"Hradec","year":"2013","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1185\/03007995.2013.781503","article-title":"Reduction in cardiovascular risk using proactive multifactorial intervention versus usual care in younger (< 65 years) and older (\u2265 65 years) patients in the CRUCIAL trial","volume":"29","author":"Kim","year":"2013","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1185\/03007995.2012.725391","article-title":"Changes in calculated coronary heart disease risk using proactive multifactorial intervention versus continued usual care in Latin-American and non-Latin-American patients enrolled in the CRUCIAL trial","volume":"28","author":"Pavia","year":"2012","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1097\/01.hjh.0000379022.25815.dc","article-title":"Cardiovascular risk factor management: single-pill amlodipine\/atorvastatin versus usual care in patients with hypertension and additional risk factors - the CRUCIAL trial","volume":"Conference","author":"Pavia","year":"2010","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1097\/01.hjh.0000379016.95320.39","article-title":"Treatment strategies for cardiovascular risk factor management in patients with hypertension and additional risk factors-experiences from the usual care arm of the CRUCIAL trial","volume":"Conference","author":"Pavia","year":"2010","journal-title":"Journal of Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD009868.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1185\/03007995.2011.555754","article-title":"Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: The CRUCIAL trial","volume":"27","author":"Zamorano","year":"2011","journal-title":"Current Medical Research and Opinion"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1751-7176.2008.00058.x","article-title":"The use of a single-pill calcium channel blocker\/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study","volume":"11","author":"Neutel","year":"2009","journal-title":"Journal of Clinical Hypertension"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.jacc.2014.08.021","article-title":"A polypill strategy to improve adherence: results from the FOCUS project","volume":"64","author":"Castellano","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ahj.2011.08.012","article-title":"The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives","volume":"165","author":"Sanz","year":"2011","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Selak V Elley C Crengle S Wadham A Rafter N Bullen C Polypills for high risk patients: results of a New Zealand randomised controlled trial Heart Lung and Circulation 2014 e13","DOI":"10.1016\/j.hlc.2014.04.159"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"g3318","DOI":"10.1136\/bmj.g3318","article-title":"Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care","volume":"348","author":"Selak","year":"2014","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.cct.2011.07.006","article-title":"IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care","volume":"32","author":"Selak","year":"2011","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1177\/2047487316637196","article-title":"Polypill-based therapy likely to reduce ethnic inequities in use of cardiovascular preventive medications: findings from a pragmatic randomised controlled trial","volume":"23","author":"Selak","year":"2016","journal-title":"European Journal of Preventive Cardiology"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.5694\/mja14.00266","article-title":"An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial","volume":"201","author":"Laba","year":"2014","journal-title":"Medical Journal of Australia"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1177\/1060028015570468","article-title":"Patient preferences for a polypill for the prevention of cardiovascular diseases","volume":"49","author":"Laba","year":"2015","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5694\/mja14.00581","article-title":"Facilitators and barriers to implementation of a pragmatic clinical trial in Aboriginal health services","volume":"203","author":"Liu","year":"2015","journal-title":"Medical Journal of Australia"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0019|cit19","first-page":"301","article-title":"Patients' and providers' perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial","volume":"8","author":"Liu","year":"2015","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/1471-2458-10-458","article-title":"Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk","volume":"10","author":"Liu","year":"2010","journal-title":"BMC Public Health"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1177\/2047487314530382","article-title":"A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk","volume":"22","author":"Patel","year":"2015","journal-title":"European Journal of Preventive Cardiology"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/1755-5922.12151","article-title":"The effect of a cardiovascular polypill strategy on pill burden","volume":"33","author":"Truelove","year":"2015","journal-title":"Cardiovascular Therapy"},{"issue":"9","key":"10.1002\/14651858.CD009868.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1742-1241.2010.02412.x","article-title":"A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors","volume":"64","author":"Malekzadeh","year":"2010","journal-title":"International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.2147\/DDDT.S112873","article-title":"Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong)","volume":"10","author":"Park","year":"2016","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1177\/2047487315624523","article-title":"Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease","volume":"23","author":"Lafeber","year":"2016","journal-title":"European Journal of Preventive Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD009868.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"e19857","DOI":"10.1371\/journal.pone.0019857","article-title":"An international randomised placebo-controlled trial of a four-component combination pill (\"polypill\") in people with raised cardiovascular risk","volume":"6","author":"PILL","year":"2011","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1745-6215-12-3","article-title":"A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization","volume":"12","author":"Soliman","year":"2011","journal-title":"Trials"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1745-6215-12-3","article-title":"A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization","volume":"5","author":"Soliman","year":"2011","journal-title":"Trials"},{"issue":"9672","key":"10.1002\/14651858.CD009868.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(09)60611-5","article-title":"Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial","volume":"373","author":"Yusuf","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/VHRM.S7710","article-title":"Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine\/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial","volume":"6","author":"Grimm","year":"2010","journal-title":"Vascular Health & Risk Management"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0031|cit31","first-page":"A120","article-title":"The critical importance of treating absolute cardiovascular risk as opposed to individual cardiovascular risk factors in isolation","volume":"Conference","author":"Grimm","year":"2009","journal-title":"Journal of Clinical Hypertension"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"e002313","DOI":"10.1136\/bmjopen-2012-002313","article-title":"INterpreting the Processes of the UMPIRE Trial (INPUT): protocol for a qualitative process evaluation study of a fixed-dose combination (FDC) strategy to improve adherence to cardiovascular medications","volume":"3","author":"Salam","year":"2013","journal-title":"BMJ Open"},{"issue":"2","key":"10.1002\/14651858.CD009868.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/2047487312463278","article-title":"Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe","volume":"21","author":"Thom","year":"2014","journal-title":"European Journal of Preventive Cardiology"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2013.277064","article-title":"Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial","volume":"310","author":"Thom","year":"2013","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"e008018","DOI":"10.1136\/bmjopen-2015-008018","article-title":"Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease","volume":"5","author":"Wood","year":"2015","journal-title":"BMJ Open"},{"issue":"7","key":"10.1002\/14651858.CD009868.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"e41297","DOI":"10.1371\/journal.pone.0041297","article-title":"Randomised polypill crossover trial in people aged 50 and over","volume":"7","author":"Wald","year":"2012","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1751-7176.2012.00696.x","article-title":"Role of single-pill combination therapy in optimizing blood pressure control in high-risk hypertension patients and management of treatment-related adverse events","volume":"14","author":"Abdellatif","year":"2012","journal-title":"Journal of Clinical Hypertension (Greenwich)"},{"issue":"2","key":"10.1002\/14651858.CD009868.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12325-013-0090-8","article-title":"Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients","volume":"31","author":"Agabiti-Rosei","year":"2014","journal-title":"Advances in Therapy"},{"issue":"8","key":"10.1002\/14651858.CD009868.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1097\/HJH.0b013e32836157be","article-title":"Blood pressure response with fixed-dose combination therapy: comparing hydrochlorothiazide with amlodipine through individual-level meta-analysis","volume":"31","author":"Agarwal","year":"2013","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0040|cit40","first-page":"8","article-title":"I take medications for blood pressure, cholesterol and other conditions. I have a two-part question: are there any long-term problems from taking a dozen or so pills a day, and has there been much progress in developing a \"polypill\" that combines several drugs into a single pill?","volume":"13","author":"Anonymous","year":"2010","journal-title":"Heart Adviser"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0041|cit41","first-page":"4","article-title":"Doubts surround study results touting polypill's benefits. The experimental pill contains four heart medications","volume":"14","author":"Anonymous","year":"2011","journal-title":"Heart Adviser"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0042|cit42","first-page":"5","article-title":"Treating many conditions--with just one pill. The polypill could make your medicines much easier to take","volume":"20","author":"Anonymous","year":"2012","journal-title":"Harvard Women's Health Watch"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0043|cit43","first-page":"78","article-title":"Hypertension: improved therapy adherence after switch to a fixed drug combinations","volume":"154","author":"Anonymous","year":"2012","journal-title":"MMW Fortschritte der Medizin"},{"issue":"7","key":"10.1002\/14651858.CD009868.pub3-BIB0044|cit44","first-page":"5","article-title":"Coming soon: many drugs in one pill. Multidrug combinations may make medicines easier to swallow","volume":"23","author":"Anonymous","year":"2013","journal-title":"Harvard Heart Letter"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub3-BIB0045|cit45","first-page":"66","article-title":"Combined heart protection for the hypertensive patient","volume":"155","author":"Anonymous","year":"2013","journal-title":"MMW Fortschritte der Medizin"},{"issue":"7","key":"10.1002\/14651858.CD009868.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1185\/03007995.2013.805536","article-title":"Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients","volume":"29","author":"Athyros","year":"2013","journal-title":"Current Medical Research and Opinion"},{"issue":"40","key":"10.1002\/14651858.CD009868.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.2174\/1381612820666140620115756","article-title":"Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease","volume":"20","author":"Athyros","year":"2014","journal-title":"Current Pharmaceutical Design"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0048|cit48","first-page":"97","article-title":"Efficacy of fix dose combination (atorvastatin and amlodipine) in treatment of uncontrolled hypertension and dyslipidemia","volume":"23","author":"Bashir","year":"2011","journal-title":"Journal of Ayub Medical College Abbottabad"},{"issue":"5","key":"10.1002\/14651858.CD009868.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"e007111","DOI":"10.1136\/bmjopen-2014-007111","article-title":"Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK","volume":"5","author":"Becerra","year":"2015","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"E813","DOI":"10.1016\/S0735-1097(13)60813-X","article-title":"Eligibility for polypill therapy, subclinical atherosclerosis, and cardiovascular events-national implications for the appropriate use of preventive pharmacotherapy: multi-ethnic study of atherosclerosis (MESA)","volume":"1","author":"Bittencourt","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD009868.pub3-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jacc.2013.08.1640","article-title":"Polypill therapy, subclinical atherosclerosis, and cardiovascular events - implications for the use of preventive pharmacotherapy","volume":"63","author":"Bittencourt","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1358\/dot.2007.43.3.1079878","article-title":"A single-pill combination of amlodipine besylate and atorvastatin calcium (update)","volume":"43","author":"Blank","year":"2007","journal-title":"Drugs of Today"},{"issue":"8","key":"10.1002\/14651858.CD009868.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/HJH.0b013e328361d016","article-title":"Initial single-pill combination therapy for cardiovascular risk factor management: it is not just convenience","volume":"31","author":"Briasoulis","year":"2013","journal-title":"Journal of Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1071\/HC13028","article-title":"Could the polypill improve adherence? The patient perspective","volume":"5","author":"Bryant","year":"2013","journal-title":"Journal of Primary Health Care"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1345\/aph.1Q621","article-title":"A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke","volume":"46","author":"Carey","year":"2012","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0056|cit56","first-page":"33","article-title":"A pragmatic trial of a polypill-based strategy to improve adherence to indicated preventive treatments among people at high cardiovascular disease risk","volume":"18","author":"Cass","year":"2013","journal-title":"Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD009868.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.cjca.2014.02.016","article-title":"Evolution of the polypill concept and ongoing clinical trials","volume":"30","author":"Castellano","year":"2014","journal-title":"Canadian Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD009868.pub3-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jacc.2014.06.009","article-title":"A polypill strategy to improve global secondary cardiovascular prevention from concept to reality","volume":"64","author":"Castellano","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0167-5273(15)31027-5","article-title":"The cardiovascular polypill: clinical data and ongoing studies","volume":"201","author":"Castellano","year":"2015","journal-title":"International Journal of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD009868.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"883","DOI":"10.5414\/CP202412","article-title":"Pharmacokinetics of a telmisartan\/rosuvastatin fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects","volume":"53","author":"Chae","year":"2015","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD009868.pub3-BIB0061|cit61","first-page":"91","article-title":"Consensus recommendation on the development of cardiovascular disease polypill in China","volume":"41","author":"Chinese","year":"2013","journal-title":"Chung Hua Hsin Hsueh Kuan Ping Tsa Chih"},{"issue":"4","key":"10.1002\/14651858.CD009868.pub3-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.amjcard.2014.05.049","article-title":"Future of polypill use for the prevention of cardiovascular disease and strokes","volume":"114","author":"Chrysant","year":"2014","journal-title":"The American Journal of Cardiology"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nrd3855","article-title":"Trial watch: dual-acting combination meets heart failure end point","volume":"11","author":"Crunkhorn","year":"2012","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1358\/dot.2013.49.5.1950148","article-title":"Polypill strategy for primary prevention of cardiovascular disorders","volume":"49","author":"Dabhadkar","year":"2013","journal-title":"Drugs Today"},{"issue":"4","key":"10.1002\/14651858.CD009868.pub3-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009868.pub2","article-title":"Fixed-dose combination therapy for the prevention of cardiovascular disease","author":"Cates","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"18","key":"10.1002\/14651858.CD009868.pub3-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1517\/14656566.2012.742064","article-title":"Atorvastatin calcium plus amlodipine for the treatment of hypertension","volume":"13","author":"Delgado-Montero","year":"2012","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1177\/1741826711418165","article-title":"Is there a BP benefit of changing the time of aspirin administration in treated hypertensive patients?","volume":"19","author":"Dimitrov","year":"2012","journal-title":"European Journal of Preventive Cardiology"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0068|cit68","unstructured":"Dresser G Nelson S Mahon J Zou G Vandervoort M Wong C Single pill combination therapy for treatment of hypertension in the combined stitch and STITCH2 study populations Journal of Clinical Hypertension 2012"},{"issue":"8","key":"10.1002\/14651858.CD009868.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1097\/HJH.0b013e3283619d6a","article-title":"Simplified therapeutic intervention to control hypertension and hypercholesterolemia: a cluster randomized controlled trial (STITCH2)","volume":"31","author":"Dresser","year":"2013","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"e52145","DOI":"10.1371\/journal.pone.0052145","article-title":"The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials","volume":"7","author":"Elley","year":"2012","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s12325-012-0075-z","article-title":"Slovak trial on cardiovascular risk reduction following national guidelines with CaDUET (the STRONG DUET study)","volume":"30","author":"Fedacko","year":"2013","journal-title":"Advances in Therapy"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1185\/03007995.2012.713339","article-title":"Impact of age and gender on blood pressure and low-density lipoprotein cholesterol reduction: results of a pooled analysis","volume":"28","author":"Feldman","year":"2012","journal-title":"Current Medical Research and Opinion"},{"issue":"5","key":"10.1002\/14651858.CD009868.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cjca.2014.03.011","article-title":"Increasing appreciation for the role of single-pill combinations for the prevention of atherosclerotic disease: a pro-polypill polemic","volume":"30","author":"Feldman","year":"2014","journal-title":"Canadian Journal of Cardiology"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/acm.2011.0187","article-title":"Natural polypill Xuezhikang: its clinical benefit and potential multicomponent synergistic mechanisms of action in cardiovascular disease and other chronic conditions","volume":"18","author":"Feng","year":"2012","journal-title":"Journal of Alternative and Complementary Medicine"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ejim.2011.06.004","article-title":"Effects of renin-angiotensin blockers\/inhibitors and statins on mortality and functional impairment in polypathological patients","volume":"23","author":"Galindo-Ocana","year":"2012","journal-title":"European Journal of Internal Medicine"},{"issue":"9","key":"10.1002\/14651858.CD009868.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/jama.2013.277066","article-title":"Progress with the polypill?","volume":"310","author":"Gaziano","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s15006-014-0046-1","article-title":"Health and longevity by one tablet daily. Fiction and hard facts on the polypill","volume":"156","author":"Holzgreve","year":"2014","journal-title":"MMW Fortschritte der Medizin"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fnagi.2016.00206","article-title":"Combined treatment with amlodipine and atorvastatin calcium reduces circulating levels of intercellular adhesion molecule-1 and tumor necrosis factor-alpha in hypertensive patients with prediabetes","volume":"8","author":"Huang","year":"2016","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"5","key":"10.1002\/14651858.CD009868.pub3-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1755-5922.2011.00280.x","article-title":"Novel treatments for cardiovascular disease prevention","volume":"30","author":"Huffman","year":"2012","journal-title":"Cardiovascular Therapeutics"},{"issue":"14","key":"10.1002\/14651858.CD009868.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jacc.2013.08.1665","article-title":"Polypills: essential medicines for cardiovascular disease secondary prevention?","volume":"63","author":"Huffman","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1111\/j.1475-6773.2012.01462.x","article-title":"Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction","volume":"47","author":"Ito","year":"2012","journal-title":"Health Services Research"},{"issue":"6","key":"10.1002\/14651858.CD009868.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1177\/1074248413492907","article-title":"Fixed combination of amlodipine\/atorvastatin: from mechanisms to trials","volume":"18","author":"Ivanovic","year":"2013","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD009868.pub3-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1371\/journal.pone.0092955","article-title":"Blood pressure control with a single-pill combination of indapamide sustained-release and amlodipine in patients with hypertension: The EFFICIENT Study","volume":"9","author":"Jadhav","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1002\/14651858.CD009868.pub3-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"225","DOI":"10.4070\/kcj.2015.45.3.225","article-title":"Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients","volume":"45","author":"Jang","year":"2015","journal-title":"Korean Circulation Journal"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0085|cit85","first-page":"2471","article-title":"The polypill concept: the story so far. [Erratum appears in European Heart Journal 2012 Mar; 33(5):551]","volume":"32","author":"Jaques","year":"2011","journal-title":"European Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD009868.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00380-014-0522-7","article-title":"Impact of combined lipid lowering with blood pressure control on coronary plaque regression: rationale and design of MILLION study","volume":"30","author":"Kawashiri","year":"2015","journal-title":"Heart Vessels"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1475-2840-11-134","article-title":"Olmesartan\/amlodipine\/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study","volume":"11","author":"Kereiakes","year":"2012","journal-title":"Cardiovascular Diabetology"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jconrel.2015.09.028","article-title":"3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles","volume":"217","author":"Khaled","year":"2015","journal-title":"Journal of Controlled Release"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.gheart.2014.03.1367","article-title":"Using DCE to assess adherence and treatment preferences for combination therapies for cardiovascular disease","volume":"1","author":"Laba","year":"2014","journal-title":"Global Heart"},{"issue":"7","key":"10.1002\/14651858.CD009868.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"A482","DOI":"10.1016\/j.jval.2014.08.1398","article-title":"Can a CVD polypill save money in the 'real world'?","volume":"17","author":"Laba","year":"2014","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0091|cit91","first-page":"A3070","article-title":"Cardiovascular polypill in high risk patients","volume":"155","author":"Lafeber","year":"2011","journal-title":"Nederlands Tijdschrift Voor Geneeskunde"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1177\/1741826711428066","article-title":"The cardiovascular polypill in high-risk patients","volume":"19","author":"Lafeber","year":"2012","journal-title":"European Journal of Preventive Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD009868.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1177\/2047487312449587","article-title":"The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus","volume":"20","author":"Lafeber","year":"2013","journal-title":"European Journal of Preventive Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD009868.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ahj.2013.04.011","article-title":"The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease","volume":"166","author":"Lafeber","year":"2013","journal-title":"American Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD009868.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1177\/2047487313476961","article-title":"The Evening versus Morning Polypill Utilization Study: The TEMPUS rationale and design","volume":"21","author":"Lafeber","year":"2014","journal-title":"European Journal of Preventive Cardiology"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"AP381","DOI":"10.1161\/circ.129.suppl_1.p381","article-title":"Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk","volume":"129","author":"Lafeber","year":"2014","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"AP445","DOI":"10.1161\/circ.129.suppl_1.p445","article-title":"A randomized controlled trial of a cardiovascular fixed-dose combination pill (polypill) treatment strategy compared with usual care on carotid intima media thickness progression in individuals at high risk of cardiovascular disease","volume":"129","author":"Lafeber","year":"2014","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0098|cit98","first-page":"S132","article-title":"The effect of morning or evening use of a fixed-dose combination pill (polypill) on LDL-cholesterol, ambulatory blood pressure and adherence in patients with cardiovascular disease","volume":"1","author":"Lafeber","year":"2014","journal-title":"European Journal of Preventive Cardiology"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijcard.2014.11.176","article-title":"Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial","volume":"181","author":"Lafeber","year":"2015","journal-title":"International Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD009868.pub3-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11906-016-0648-3","article-title":"Multifactorial prevention of cardiovascular disease in patients with hypertension: the cardiovascular polypill","volume":"18","author":"Lafeber","year":"2016","journal-title":"Current Hypertension Reports"},{"issue":"6","key":"10.1002\/14651858.CD009868.pub3-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/01.coh.0000247389.08485.87","article-title":"Cardiovascular complications of HIV: an overview of risk and a novel approach to prevention - the HIV polypill study","volume":"1","author":"Law","year":"2006","journal-title":"Current Opinion in HIV and AIDS"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1016\/j.gheart.2014.03.1644","article-title":"Understanding adherence to a cardiovascular polypill strategy-a process evaluation of a pragmatic clinical trial","volume":"1","author":"Liu","year":"2014","journal-title":"Global Heart"},{"issue":"3","key":"10.1002\/14651858.CD009868.pub3-BIB0103|cit103","first-page":"301","article-title":"Patients' and providers' perspectives of a polypill strategy to improve cardiovascular prevention in Australian Primary Health Care","volume":"8","author":"Liu","year":"2015","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ijcard.2016.07.163","article-title":"Greater cardiovascular risk reduction with once-daily fixed combination of three antihypertensive agents and statin versus free-drug combination: The ALL-IN-ONE trial","volume":"222","author":"Marazzi","year":"2016","journal-title":"International Journal of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD009868.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"A475","DOI":"10.1016\/j.jval.2014.08.1356","article-title":"Pharmacoeconomic grounding of using polypill amlodipine with atorvastatin versus monodrugs in patients with hypertension and dyslipidemia in Ukraine","volume":"17","author":"Mishchenko","year":"2014","journal-title":"Value in Health"},{"issue":"12","key":"10.1002\/14651858.CD009868.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1001\/jamainternmed.2015.5941","article-title":"Targeting vascular risk factors in older adults: from polypill to personalized prevention","volume":"175","author":"Mossello","year":"2015","journal-title":"JAMA Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub3-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1751-7176.2008.00058.x","article-title":"The use of a single-pill calcium channel blocker\/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study","volume":"11","author":"Neutel","year":"2009","journal-title":"Journal of Clinical Hypertension"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/CRD.0b013e3182755429","article-title":"The polypill a potential global solution to cardiovascular disease","volume":"21","author":"Nguyen","year":"2013","journal-title":"Cardiology in Review"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijcard.2014.09.029","article-title":"Real-life use of the polypill components (ASA+ACEI+statins) after an acute coronary syndrome and long-term mortality","volume":"177","author":"Oliveras Vila","year":"2014","journal-title":"International Journal of Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD009868.pub3-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/jech-2013-203220","article-title":"Polypill is not a 'vaccine-like' solution for primary cardiovascular disease prevention in all parts of the world","volume":"67","author":"Reiner","year":"2013","journal-title":"Journal of Epidemiology and Community Health"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1475-9276-12-44","article-title":"Recruiting equal numbers of indigenous and non-indigenous participants to a 'polypill' randomized trial","volume":"12","author":"Selak","year":"2013","journal-title":"International Journal for Equity in Health"},{"issue":"13","key":"10.1002\/14651858.CD009868.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1177\/2047487316638216","article-title":"Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease","volume":"23","author":"Selak","year":"2016","journal-title":"European Journal of Preventive Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD009868.pub3-BIB0113|cit113","first-page":"531","article-title":"Cardiovascular disease prevention using fixed dose pharmacotherapy in Iran: updated meta-analyses and mortality estimation","volume":"15","author":"Sepanlou","year":"2012","journal-title":"Archives of Iranian Medicine"},{"issue":"19","key":"10.1002\/14651858.CD009868.pub3-BIB0114|cit114","first-page":"e803","article-title":"Comparison of risk factor reduction and tolerability of a full dose versus low dose of a polypill (polycap) in individuals at high risk of cardiovascular diseases: a phase II, double blind randomized trial","volume":"125","author":"Sigamani","year":"2012","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD009868.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1556\/650.2016.30401","article-title":"One year persistence of atorvastatin and amlodipine fixed dose combination versus atorvastatin therapy","volume":"157","author":"Simonyi","year":"2016","journal-title":"Orvosi Hetilap"},{"issue":"7","key":"10.1002\/14651858.CD009868.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.clinthera.2013.05.016","article-title":"Pharmacokinetics of rosuvastatin\/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects","volume":"35","author":"Son","year":"2013","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1758-5996-6-56","article-title":"Effect of single tablet of fixed-dose amlodipine and atorvastatin on blood pressure\/lipid control, oxidative stress, and medication adherence in type 2 diabetic patients","volume":"6","author":"Tanaka","year":"2014","journal-title":"Diabetology and Metabolic Syndrome"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.1016\/j.gheart.2014.03.2303","article-title":"Impact of pill burden on the effects of a polypill-based strategy on use of indicated medications in people with or at high risk of cardiovascular disease","volume":"1","author":"Truelove","year":"2014","journal-title":"Global Heart"},{"issue":"4","key":"10.1002\/14651858.CD009868.pub3-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s10654-016-0122-1","article-title":"Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke","volume":"31","author":"Wald","year":"2016","journal-title":"European Journal of Epidemiology"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1097\/01.hjh.0000420580.36849.9c","article-title":"Effect of amlodipine and amlodipine plus atorvastatin on impaired vascular function in patients with hypertension","volume":"30","author":"Wang","year":"2012","journal-title":"Journal of Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijcard.2013.10.007","article-title":"Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: the SPACE Collaboration","volume":"170","author":"Webster","year":"2013","journal-title":"International Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub3-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrcardio.2013.185","article-title":"PREVENTION coronary artery calcium and polypill therapy","volume":"11","author":"Webster","year":"2014","journal-title":"Nature Reviews Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD009868.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11886-015-0673-x","article-title":"Polypill: progress and challenges to global use: update on the trials and policy implementation","volume":"17","author":"Webster","year":"2015","journal-title":"Current Cardiology Reports"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0124|cit124","first-page":"S150","article-title":"Impact of cardiovascular polypill based therapy on healthy lifestyle behavior","volume":"1","author":"Webster","year":"2015","journal-title":"European Journal of Preventive Cardiology"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijcard.2015.12.015","article-title":"Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: a prospective, individual patient data meta-analysis of 3140 patients in six countries","volume":"205","author":"Webster","year":"2016","journal-title":"International Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425247.2016.1111869","article-title":"Polypill treatments for cardiovascular diseases","volume":"13","author":"Webster","year":"2016","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1745-6215-14-354","article-title":"Cardiovascular disease risk reduction in rural China: a clustered randomized controlled trial in Zhejiang","volume":"14","author":"Wei","year":"2013","journal-title":"Trials"},{"issue":"5","key":"10.1002\/14651858.CD009868.pub3-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jacc.2013.09.044","article-title":"\"De-risking\" risk reduction should coronary artery calcium scoring be the gatekeeper to preventive pharmacotherapy with the polypill?","volume":"63","author":"Wijns","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub3-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.aogh.2013.12.008","article-title":"The concept of the polypill in the prevention of cardiovascular disease","volume":"80","author":"Wiley","year":"2014","journal-title":"Annals of Global Health"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0130|cit130","first-page":"446","article-title":"Intervention effects and safety of cardiovascular polypill for the relevant risk factors of coronary heart disease: a systematic review","volume":"13","author":"Xing","year":"2013","journal-title":"Chinese Journal of Evidence-Based Medicine"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.12659\/msm.896843","article-title":"Is time an important problem in management of hypertension and hypercholesterolemia by using an amlodipine-atorvastatin single pill combination?","volume":"22","author":"Zeng","year":"2016","journal-title":"Medical Science Monitor"},{"issue":"2","key":"10.1002\/14651858.CD009868.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40256-013-0019-2","article-title":"Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis","volume":"13","author":"Zomer","year":"2013","journal-title":"American Journal of Cardiovascular Drugs"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0133|cit133","doi-asserted-by":"crossref","unstructured":"Fommei E Ghione S Biagini S Corrao G Mancia G A proposal for the idea of a flexible-combination polypill in arterial hypertension Journal of Hypertension 2015 e258","DOI":"10.1097\/01.hjh.0000468143.29123.1c"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0134|cit134","unstructured":"NCT00530946 A randomized study to evaluate efficacy and safety of a fixed combination therapy of amlodipine and atorvastatin clinicaltrials.gov\/ct2\/show\/NCT00530946"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0135|cit135","unstructured":"NCT01004705 Cardiovascular fixed dose combination pill: a pharmacodynamic study of a fixed dose combination of acetylsalicylic acid, simvastatin, and ramipril in subjects with elevated LDL cholesterol clinicaltrials.gov\/ct2\/show\/NCT01004705"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0136|cit136","unstructured":"NCT01005290 Cardiovascular fixed dose combination pill: a pharmacodynamic interaction study to evaluate the effect of a fixed dose combination of acetylsalicylic acid, simvastatin and ramipril (cardiovascular fixed dose combination pill) on blood pressure clinicaltrials.gov\/ct2\/show\/NCT01005290"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0137|cit137","unstructured":"NCT01362218 Cardiovascular fixed combination pill ASR: pharmacodynamic clinical trial of a fixed dose combination of acetylsalicylic acid, simvastatin, and ramipril (cardiovascular polypill) on LDL cholesterol clinicaltrials.gov\/ct2\/show\/NCT01362218"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0138|cit138","unstructured":"NCT01406431 A single dose, sequence-randomized, open-label, 2x2 crossover study to compare pharmacokinetics between pitavastatin and valsartan co-administration and Livalo\u00ae fixed combination drug in healthy male subjects clinicaltrials.gov\/ct2\/show\/NCT01406431"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0139|cit139","unstructured":"NCT01764178 A single dose, sequence-randomized, open-label, 2x2 crossover study to compare pharmacokinetics between pitavastatn and valsartan co-administration and Livalo complex product in healthy male subjects clinicaltrials.gov\/ct2\/show\/NCT01764178"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0140|cit140","unstructured":"NCT02075619 An open-label, randomized, single dose, three-way crossover, six sequence pilot study to evaluate the relative bioavailability of one amlodipine 10mg tablet and rosuvastatin 20mg tablet to two fixed dose combination tablet formulations of amlodipine (10mg) and rosuvastatin (20mg) in healthy adult male and female subjects under fasting conditions clinicaltrials.gov\/ct2\/show\/NCT02075619"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0141|cit141","unstructured":"NCT02569814 A study to compare the pharmacokinetics and safety of a fixed dose combination of fimasartan\/amlodipine\/rosuvastatin clinicaltrials.gov\/ct2\/show\/NCT02569814"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0142|cit142","unstructured":"NCT02662894 Efficacy of fixed-dose combination of valsartan + rosuvastatin versus their isolated components for hypertension and dyslipidemia clinicaltrials.gov\/ct2\/show\/NCT02662894"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0143|cit143","unstructured":"NCT02791958 Pharmacodynamic equivalence study of ramipril 10 mg and atorvastatin 40 mg administered as a cardiovascular fixed dose combination pill AAR as compared to monotherapy with the reference products Altace\u00ae 10 mg and Lipitor\u00ae 40 mg clinicaltrials.gov\/ct2\/show\/NCT02791958"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0144|cit144","unstructured":"NCT02842359 Efficacy evaluation of metabolic, anti-inflammatory, and antioxidative factors of irbesartan\/atorvastatin fixed-dose combination in type 2 diabetic patients diagnosed with hyperlipidemia and hypertension, with adequately controlled blood glucose levels clinicaltrials.gov\/ct2\/show\/NCT02842359"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13012-016-0488-1","article-title":"An integrated general practice and pharmacy-based intervention to promote the use of appropriate preventive medications among individuals at high cardiovascular disease risk: protocol for a cluster randomized controlled trial","volume":"11","author":"Hayek","year":"2016","journal-title":"Implementation Science"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0146|cit146","doi-asserted-by":"crossref","unstructured":"Joshi R Patel A Peiris D Saini B Usherwood T Armor C INTegrated Electronic General practice support tool, phaRmacy led intervention And combination Therapy Evaluation trial (INTEGRATE) Heart Lung and Circulation 2015 S385","DOI":"10.1016\/j.hlc.2015.06.634"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0147|cit147","unstructured":"NCT01646437 The International Polycap Study-3 clinicaltrials.gov\/ct2\/show\/NCT01646437"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0148|cit148","unstructured":"NCT01826019 Heart Outcomes Prevention and Evaluation 4 (HOPE-4) clinicaltrials.gov\/ct2\/show\/NCT01826019"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0149|cit149","unstructured":"NCT02278471 The SCCS polypill pilot trial clinicaltrials.gov\/ct2\/show\/NCT02278471"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0150|cit150","unstructured":"NCT02596126 SEcondary prevention of Cardiovascular disease in the Elderly trial (SECURE) clinicaltrials.gov\/ct2\/show\/NCT02596126"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0151|cit151","first-page":"515","article-title":"PolyPill for prevention of cardiovascular disease in an urban Iranian population with special focus on nonalcoholic steatohepatitis: a pragmatic randomized controlled trial within a cohort (PolyIran - Liver) - study protocol","volume":"18","author":"Merat","year":"2015","journal-title":"Archives of Iranian Medicine"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0152|cit152","unstructured":"NCT01271985 Prevention of cardiovascular disease in middle-aged and elderly Iranians using a single polypill (PolyIran) clinicaltrials.gov\/ct2\/show\/NCT01271985"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1177\/2047487314550803","article-title":"Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial","volume":"22","author":"Ostovaneh","year":"2015","journal-title":"European Journal of Preventive Cardiology"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0154|cit154","first-page":"551","article-title":"Reliability analysis of a newly developed questionnaire for quality control of follow-up visits in PolyIran study","volume":"19","author":"Roshandel","year":"2016","journal-title":"Archives of Iranian Medicine"},{"issue":"23","key":"10.1002\/14651858.CD009868.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"ALLHAT-investigators","year":"2002","journal-title":"JAMA"},{"issue":"24","key":"10.1002\/14651858.CD009868.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2010.840","article-title":"Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial","volume":"303","author":"Armitage","year":"2010","journal-title":"JAMA"},{"issue":"7329","key":"10.1002\/14651858.CD009868.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"ATT-Collaboration","year":"2002","journal-title":"BMJ"},{"issue":"9493","key":"10.1002\/14651858.CD009868.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"9678","key":"10.1002\/14651858.CD009868.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","article-title":"Fixed-dose combinations improve medication compliance: a meta-analysis","volume":"120","author":"Bangalore","year":"2007","journal-title":"American Journal of Medicine"},{"issue":"9775","key":"10.1002\/14651858.CD009868.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0140-6736(11)60393-0","article-title":"Priority actions for the non-communicable disease crisis","volume":"377","author":"Beaglehole","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD009868.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1012848","article-title":"Lifetime risks of cardiovascular disease","volume":"366","author":"Berry","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"9435","key":"10.1002\/14651858.CD009868.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"8693","key":"10.1002\/14651858.CD009868.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)90944-Z","article-title":"Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context","volume":"335","author":"Collins","year":"1990","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Cholesterol Treatment Trialists' Collaboration","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD009868.pub3-BIB0166|cit166","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009868.pub2","article-title":"Fixed-dose combination therapy for the prevention of cardiovascular disease","author":"Cates","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0167|cit167","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub3-BIB0168|cit168","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001561.pub3","article-title":"Multiple risk factor interventions for primary prevention of coronary heart disease","author":"Ebrahim","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7109","key":"10.1002\/14651858.CD009868.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"29","key":"10.1002\/14651858.CD009868.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"European Heart Journal"},{"issue":"7480","key":"10.1002\/14651858.CD009868.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1136\/bmj.329.7480.1447","article-title":"The polymeal: a more natural, safer, and probably tastier (than the polypill) strategy to reduce cardiovascular disease by more than 75%","volume":"329","author":"Franco","year":"2004","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD009868.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0174|cit174","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A (editors) Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October 2013 gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"issue":"2","key":"10.1002\/14651858.CD009868.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/HYPERTENSIONAHA.109.139816","article-title":"Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis","volume":"55","author":"Gupta","year":"2010","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0177|cit177","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0178|cit178","unstructured":"Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"9791","key":"10.1002\/14651858.CD009868.pub3-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0140-6736(11)60872-6","article-title":"Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials","volume":"378","author":"Holmes","year":"2011","journal-title":"Lancet"},{"issue":"9326","key":"10.1002\/14651858.CD009868.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"HPSCG","year":"2002","journal-title":"Lancet"},{"issue":"9426","key":"10.1002\/14651858.CD009868.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD009868.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jamacardio.2016.0218","article-title":"Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews","volume":"1","author":"Karmali","year":"2016","journal-title":"JAMA Cardiology"},{"issue":"9607","key":"10.1002\/14651858.CD009868.pub3-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"issue":"14","key":"10.1002\/14651858.CD009868.pub3-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0185|cit185","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of InterventionsVersion 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"20","key":"10.1002\/14651858.CD009868.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1161\/CIRCULATIONAHA.109.873232","article-title":"The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions","volume":"122","author":"Lonn","year":"2010","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD009868.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"571-81; quiz 82","DOI":"10.1111\/j.1524-6175.2006.05636.x","article-title":"Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial","volume":"8","author":"Messerli","year":"2006","journal-title":"Journal of Clinical Hypertension"},{"issue":"7","key":"10.1002\/14651858.CD009868.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/archinte.1992.00400130082009","article-title":"Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group","volume":"152","author":"Neaton","year":"1992","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0191|cit191","unstructured":"NICE Lipid Modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease www.nice.org.uk\/nicemedia\/pdf\/CG67NICEguideline.pdf"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0192|cit192","unstructured":"NICE Cardiovascular disease prevention www.nice.org.uk\/guidance\/PH25"},{"issue":"9735","key":"10.1002\/14651858.CD009868.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0140-6736(10)60834-3","article-title":"Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study","volume":"376","author":"O'Donnell","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD009868.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1097\/HJH.0b013e328310e0d9","article-title":"The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes","volume":"26","author":"Ostergren","year":"2008","journal-title":"Journal of Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD009868.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1524-6175.2003.03163.x","article-title":"Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"5","author":"Papademetriou","year":"2003","journal-title":"Journal of Clinical Hypertension"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0196|cit196","first-page":"1635","article-title":"European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)","volume":"33","author":"Perk","year":"2012","journal-title":"European Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD009868.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"e19857","DOI":"10.1371\/journal.pone.0019857","article-title":"An international randomised placebo-controlled trial of a four-component combination pill (\"polypill\") in people with raised cardiovascular risk","volume":"6","author":"Rodgers","year":"2011","journal-title":"Plos One"},{"issue":"12","key":"10.1002\/14651858.CD009868.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1177\/0091270007307879","article-title":"A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial","volume":"47","author":"Preston","year":"2007","journal-title":"Journal of Clinical Pharmacology"},{"issue":"11","key":"10.1002\/14651858.CD009868.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1161\/01.STR.0000092488.40085.15","article-title":"Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review","volume":"34","author":"Rashid","year":"2003","journal-title":"Stroke"},{"issue":"14","key":"10.1002\/14651858.CD009868.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa1406656","article-title":"Demographic and epidemiologic drivers of global cardiovascular mortality","volume":"372","author":"Roth","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"9364","key":"10.1002\/14651858.CD009868.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"issue":"25 Suppl 2","key":"10.1002\/14651858.CD009868.pub3-BIB0202|cit202","first-page":"S1","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub3-BIB0203|cit203","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004816.pub5","article-title":"Statins for the primary prevention of cardiovascular disease","author":"Taylor","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD009868.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1053\/euhj.2001.2888","article-title":"Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young","volume":"23","author":"Thomas","year":"2002","journal-title":"European Heart Journal"},{"issue":"9395","key":"10.1002\/14651858.CD009868.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials","volume":"362","author":"Turnbull","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD009868.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/ije\/dyp330","article-title":"Thirty-five-year trends in cardiovascular risk factors in Finland","volume":"39","author":"Vartiainen","year":"2010","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub3-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ypmed.2010.09.016","article-title":"Acceptance of a polypill approach to prevent cardiovascular disease among a sample of U.S. physicians","volume":"52","author":"Viera","year":"2011","journal-title":"Preventive Medicine"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"e002498","DOI":"10.1136\/bmjopen-2012-002498","article-title":"Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study","volume":"3","author":"Virdee","year":"2013","journal-title":"BMJ Open"},{"issue":"7404","key":"10.1002\/14651858.CD009868.pub3-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/bmj.326.7404.1419","article-title":"A strategy to reduce cardiovascular disease by more than 80%","volume":"326","author":"Wald","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD009868.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ypmed.2010.11.015","article-title":"The polypill in the prevention of cardiovascular disease","volume":"52","author":"Wald","year":"2011","journal-title":"Preventive Medicine"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0211|cit211","unstructured":"World Health Organization Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions. Report of WHO-Wellcome Trust meeting of experts (1-3 August 2001) apps.who.int\/iris\/bitstream\/10665\/42567\/1\/WHO_MPN_CVD_2002.01.pdf 2001"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0212|cit212","first-page":"1","article-title":"Global action plan for the prevention and control of noncommunicable diseases, 2013-202","volume":"1","author":"World Health Organization","year":"2013","journal-title":"apps.who.int\/iris\/bitstream\/10665\/94384\/1\/9789241506236_eng.pdf"},{"key":"10.1002\/14651858.CD009868.pub3-BIB0213|cit213","first-page":"1","article-title":"HEARTS Technical package for cardiovascular disease management in primary health care","volume":"1","author":"World Health Organization","year":"2016","journal-title":"www.who.int\/cardiovascular_diseases\/hearts\/Hearts_package.pdf"},{"issue":"9326","key":"10.1002\/14651858.CD009868.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0140-6736(02)09358-3","article-title":"Two decades of progress in preventing vascular disease","volume":"360","author":"Yusuf","year":"2002","journal-title":"Lancet"},{"issue":"9438","key":"10.1002\/14651858.CD009868.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"issue":"9798","key":"10.1002\/14651858.CD009868.pub3-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(11)61215-4","article-title":"Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey","volume":"378","author":"Yusuf","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD009868.pub3-BIB0217|cit217","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009868.pub2","article-title":"Fixed-dose combination therapy for the prevention of cardiovascular disease","author":"Cates","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD009868.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T02:55:16Z","timestamp":1689044116000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009868.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Heart Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,6]]},"references-count":217,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009868.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,6]]}}}